348 related articles for article (PubMed ID: 10684624)
1. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
2. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
[TBL] [Abstract][Full Text] [Related]
3. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
[TBL] [Abstract][Full Text] [Related]
4. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
[TBL] [Abstract][Full Text] [Related]
5. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
6. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
Boyer PL; Ding J; Arnold E; Hughes SH
Antimicrob Agents Chemother; 1994 Sep; 38(9):1909-14. PubMed ID: 7529011
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
Braz VA; Holladay LA; Barkley MD
Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
[TBL] [Abstract][Full Text] [Related]
9. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress.
Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Bonache MC; De Castro S
Curr Pharm Des; 2006; 12(15):1895-907. PubMed ID: 16724955
[TBL] [Abstract][Full Text] [Related]
10. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity.
Soriano E; Marco-Contelles J; Tomassi C; Nguyen Van Nhien A; Postel D
J Chem Inf Model; 2006; 46(4):1666-77. PubMed ID: 16859298
[TBL] [Abstract][Full Text] [Related]
11. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
[TBL] [Abstract][Full Text] [Related]
12. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
[TBL] [Abstract][Full Text] [Related]
13. Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase.
Venezia CF; Howard KJ; Ignatov ME; Holladay LA; Barkley MD
Biochemistry; 2006 Mar; 45(9):2779-89. PubMed ID: 16503633
[TBL] [Abstract][Full Text] [Related]
14. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
[TBL] [Abstract][Full Text] [Related]
15. The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site.
Sharaf NG; Xi Z; Ishima R; Gronenborn AM
Proteins; 2017 Dec; 85(12):2191-2197. PubMed ID: 28905420
[TBL] [Abstract][Full Text] [Related]
16. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
Sluis-Cremer N; Temiz NA; Bahar I
Curr HIV Res; 2004 Oct; 2(4):323-32. PubMed ID: 15544453
[TBL] [Abstract][Full Text] [Related]
17. Quantitative structure-activity relationship studies on some viral reverse transcriptase inhibitors acting as anti-HIV-1 agents.
Garg R; Gupta SP
J Enzyme Inhib; 1997 Jan; 11(3):171-81. PubMed ID: 9204386
[TBL] [Abstract][Full Text] [Related]
18. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
[TBL] [Abstract][Full Text] [Related]
19. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.
Velázquez S; Alvarez R; Pérez C; Gago F; De Clercq E; Balzarini J; Camarasa MJ
Antivir Chem Chemother; 1998 Nov; 9(6):481-9. PubMed ID: 9865386
[TBL] [Abstract][Full Text] [Related]
20. Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HIV-1 RT. Studies in the linker and ddN region.
Velázquez S; Tuñón V; Jimeno ML; Pérez-Pérez MJ; San-Félix A; Chamorro C; Lobatón E; Esteban-Gamboa A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides; 1999; 18(4-5):1029-30. PubMed ID: 10432737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
